Our immune system not only defends against bacterial and viral invaders but also maintains tissue integrity by eliminating abnormal cells before they develop into tumors. When a tumor forms, it establishes an immunosuppressive niche that disarms anti‑tumor immune cells, sometimes even repurposing them to inhibit broader immunity.
A key hurdle in cancer immunotherapy is that although immune cells can recognize and target malignant cells, the tumor microenvironment frequently blocks their activity and may actively suppress them. Professor Chunxia Zhao of the University of Adelaide explained, “Overcoming the oppressive tumor environment remains a barricade even for the most promising therapies,” emphasizing the critical nature of this challenge.
A recent study published in *Science Advances* reported Zhao’s team’s development of a precise delivery platform that can shuttle mRNA therapy directly to tumor‑affected areas, converting pro‑immunosuppressive macrophages into effective immune activators. The focus was on tumor‑associated macrophages, whose tumor‑derived signals normally hinder T‑cell entry and function.
The therapeutic core is mRNA instructing cells to produce CXCL9, a chemokine that attracts T lymphocytes. By limiting exposure of this signal to the desired location, the approach reduces unintended systemic inflammation and lowers the risk of severe autoimmune adverse events.
While mRNA therapies have advanced rapidly—especially following their adoption for COVID‑19 vaccines—the challenge lies in directing activation precisely where it is needed. Global immune stimulation can provoke harmful side effects if not carefully controlled.
To achieve site‑specific delivery, the researchers engineered “smart” nanoparticles equipped with antibodies that bind TREM2 receptors abundantly expressed on tumor‑associated immunosuppressive macrophages. This targeting ensures the mRNA reaches only the relevant immune cells within each tumor lesion.
Each particle also incorporates resiquimod, a compound that triggers specific immune pathways. Preliminary experiments showed that reintegrating macrophages induced robust production of CXCL9 and other activation markers such as NOS2 (upward of 90‑fold), while markers of a suppressive phenotype dropped sharply.
In vivo, mice predisposed to aggressive breast cancer received the smart nanoparticles in three sequential doses. After treatment, tumor expansion decelerated, with CXCL9 concentrations approaching four times those in control animals. T‑cell activity emerged in the tumors and neighboring lymph nodes, indicating a more resilient immune response.
The nanotherapeutic was also evaluated in combination with two commonly used checkpoint‑inhibitor agents. While the combined regimen did not further diminish tumor size, it provoked significant cellular diversification—additional T‑cell subsets penetrated the neoplasm and regional lymph node tissue, a pattern linked to the potential for a longer-lasting, durable immune defense.
